EP3347035A4 - CARTON PEPTIDES - Google Patents

CARTON PEPTIDES Download PDF

Info

Publication number
EP3347035A4
EP3347035A4 EP16845226.6A EP16845226A EP3347035A4 EP 3347035 A4 EP3347035 A4 EP 3347035A4 EP 16845226 A EP16845226 A EP 16845226A EP 3347035 A4 EP3347035 A4 EP 3347035A4
Authority
EP
European Patent Office
Prior art keywords
peptides
cartilage
locating
locating cartilage
peptides locating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16845226.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3347035A2 (en
Inventor
James Olson
Andrew David STRAND
Emily June GIRARD
Roland STRONG
Christopher Mehlin
Colin CORRENTI
Natalie NAIRN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blaze Bioscience Inc
Fred Hutchinson Cancer Center
Original Assignee
Blaze Bioscience Inc
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blaze Bioscience Inc, Fred Hutchinson Cancer Center filed Critical Blaze Bioscience Inc
Publication of EP3347035A2 publication Critical patent/EP3347035A2/en
Publication of EP3347035A4 publication Critical patent/EP3347035A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Insects & Arthropods (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16845226.6A 2015-09-09 2016-09-09 CARTON PEPTIDES Withdrawn EP3347035A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562216331P 2015-09-09 2015-09-09
US201662278929P 2016-01-14 2016-01-14
US201662385734P 2016-09-09 2016-09-09
PCT/US2016/051166 WO2017044894A2 (en) 2015-09-09 2016-09-09 Cartilage-homing peptides

Publications (2)

Publication Number Publication Date
EP3347035A2 EP3347035A2 (en) 2018-07-18
EP3347035A4 true EP3347035A4 (en) 2019-05-01

Family

ID=58240183

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16845226.6A Withdrawn EP3347035A4 (en) 2015-09-09 2016-09-09 CARTON PEPTIDES

Country Status (9)

Country Link
US (3) US11090358B2 (enExample)
EP (1) EP3347035A4 (enExample)
JP (2) JP6966424B2 (enExample)
CN (1) CN108135970B (enExample)
AU (1) AU2016321342A1 (enExample)
BR (1) BR112018004536A2 (enExample)
CA (1) CA2994865A1 (enExample)
IL (1) IL257396B (enExample)
WO (1) WO2017044894A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754072C (en) 2009-03-02 2019-01-15 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
CA3214092A1 (en) 2011-03-15 2012-09-20 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CN108135970B (zh) 2015-09-09 2023-09-01 弗莱德哈钦森癌症中心 软骨归巢肽
US11448643B2 (en) 2016-04-08 2022-09-20 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
WO2017193070A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
WO2018049285A1 (en) 2016-09-09 2018-03-15 Fred Hutchinson Cancer Research Center Stable peptides and methods of use thereof
AU2018210157B2 (en) 2017-01-18 2022-10-06 Fred Hutchinson Cancer Center Peptide compositions and methods of use thereof for disrupting TEAD interactions
EP3595699A4 (en) * 2017-03-16 2020-12-23 Blaze Bioscience, Inc. PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
CA3064436A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
IT201700071296A1 (it) 2017-06-26 2018-12-26 Alda S R L Nuovi reagenti per microscopia ottica
AU2018388583A1 (en) 2017-12-19 2020-06-11 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
EP3773668A4 (en) * 2018-03-16 2022-10-19 Blaze Bioscience, Inc. Truncated cartilage-homing peptides and peptide complexes and methods of use thereof
WO2019209662A1 (en) * 2018-04-23 2019-10-31 Fred Hutchinson Cancer Research Center Conjugates of cartilage-homing peptides
WO2020068920A2 (en) 2018-09-25 2020-04-02 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
CN110357950B (zh) * 2019-07-29 2023-04-25 武汉大学 酸性氨基酸扫描法设计的免疫抑制多肽及应用
CN111454334B (zh) * 2020-03-30 2021-12-14 东北农业大学 一种抗酶解的抗菌肽ii4ii及制备方法和应用
CN111840512B (zh) * 2020-07-15 2023-06-09 广州领晟医疗科技有限公司 治疗软骨修复和/或骨关节炎的组合物
CN113332442A (zh) * 2021-06-10 2021-09-03 愈美明德(成都)生物医药科技有限公司 一种靶向递送分子、粒子及其制备方法、应用
CN118091163B (zh) * 2024-04-26 2024-07-02 山东省食品药品检验研究院 一种鉴别尖刺信使蝎的特征多肽及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179560A1 (en) * 2012-12-10 2014-06-26 Fred Hutchinson Cancer Research Center Drug discovery methods and platforms
WO2016210376A2 (en) * 2015-06-26 2016-12-29 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2269060C (en) 1996-10-17 2009-04-07 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2001053342A1 (en) 2000-01-21 2001-07-26 The Burnham Institute Chimeric prostate-homing peptides with pro-apoptotic activity
JP2005511017A (ja) 2001-09-05 2005-04-28 キングス カレッジ ロンドン ホーミングペプチド
WO2003082196A2 (en) 2002-03-26 2003-10-09 The General Hospital Corporation Combination therapy using trefoil peptides
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
FR2877946B1 (fr) 2004-11-12 2011-02-11 Commissariat Energie Atomique Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet
CN101583370A (zh) 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
US7592009B2 (en) * 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
JP5463013B2 (ja) 2007-06-19 2014-04-09 国立大学法人 岡山大学 軟骨マーカー
CN101918041A (zh) 2007-10-12 2010-12-15 超分子有限公司 用于肿瘤诊断和治疗的氯毒素剂的系统性给药
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
WO2011142858A2 (en) 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
US20130280281A1 (en) 2010-07-02 2013-10-24 Jean-Paul Castaigne Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
AU2011326164B2 (en) 2010-11-08 2016-05-05 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
US10426850B2 (en) 2011-11-22 2019-10-01 The Johns Hopkins University Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use
WO2013078250A2 (en) 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
JP5724937B2 (ja) 2012-04-23 2015-05-27 ニプロ株式会社 腎臓集積性を示すペプチド、製剤
CN104884473B (zh) 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
WO2014004465A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
SI2994153T1 (sl) 2013-05-07 2018-12-31 Merck Patent Gmbh Peptidi in konjugati peptid-učinkovina za renalno ciljanje
CA2916725A1 (en) * 2013-07-22 2015-01-29 Kineta One, Llc Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
US20170050988A1 (en) * 2013-11-25 2017-02-23 Sanofi Dotam derivatives for therapeutic use
US20160338967A1 (en) 2013-12-23 2016-11-24 Kineta One, Llc Sustained release depot formulations of therapeutic proteins, and uses thereof
CN111620940A (zh) 2014-05-21 2020-09-04 哈佛大学的校长及成员们 Ras抑制肽和其用途
CN107405388A (zh) 2015-01-08 2017-11-28 衣阿华大学研究基金会 用于体内关节软骨再生的方法
WO2016112208A2 (en) 2015-01-09 2016-07-14 Kineta One, Llp Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
WO2016118859A1 (en) 2015-01-22 2016-07-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells comprising flip
CN106380521B (zh) 2015-07-02 2020-12-29 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
CN108135970B (zh) 2015-09-09 2023-09-01 弗莱德哈钦森癌症中心 软骨归巢肽
WO2017100700A2 (en) 2015-12-11 2017-06-15 Fred Hutchinson Cancer Research Center Peptides for renal therapy
CA3053242A1 (en) 2016-02-19 2017-08-24 Dignity Health Antibody fusion protein and related compositions for targeting cancer
WO2018049285A1 (en) 2016-09-09 2018-03-15 Fred Hutchinson Cancer Research Center Stable peptides and methods of use thereof
WO2018119001A1 (en) 2016-12-19 2018-06-28 Fred Hutchinson Cancer Research Center Peptide-antibody compositions and methods of use thereof
AU2018210157B2 (en) 2017-01-18 2022-10-06 Fred Hutchinson Cancer Center Peptide compositions and methods of use thereof for disrupting TEAD interactions
EP3595699A4 (en) 2017-03-16 2020-12-23 Blaze Bioscience, Inc. PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
CA3064436A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179560A1 (en) * 2012-12-10 2014-06-26 Fred Hutchinson Cancer Research Center Drug discovery methods and platforms
WO2016210376A2 (en) * 2015-06-26 2016-12-29 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARAH J. MOORE ET AL: "Knottins: disulfide-bonded therapeutic and diagnostic peptides", DRUG DISCOVERY TODAY: TECHNOLOGIES, vol. 9, no. 1, 1 March 2012 (2012-03-01), AMSTERDAM, NL, pages e3 - e11, XP055567927, ISSN: 1740-6749, DOI: 10.1016/j.ddtec.2011.07.003 *

Also Published As

Publication number Publication date
EP3347035A2 (en) 2018-07-18
AU2016321342A1 (en) 2018-04-26
IL257396B (en) 2020-06-30
US11648290B2 (en) 2023-05-16
CN108135970B (zh) 2023-09-01
WO2017044894A3 (en) 2017-05-11
CA2994865A1 (en) 2017-03-16
WO2017044894A2 (en) 2017-03-16
JP6966424B2 (ja) 2021-11-17
IL257396A (en) 2018-04-30
JP2018527348A (ja) 2018-09-20
US11090358B2 (en) 2021-08-17
JP2022009342A (ja) 2022-01-14
US20190117728A1 (en) 2019-04-25
CN108135970A (zh) 2018-06-08
JP7378449B2 (ja) 2023-11-13
US20220016202A1 (en) 2022-01-20
US20230364183A1 (en) 2023-11-16
BR112018004536A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
EP3347035A4 (en) CARTON PEPTIDES
IL254516A0 (en) Proteins specific for cd137
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
EP3316375A4 (en) Redox flow cell
DK3305788T3 (da) Janus-kinase-hæmmer
DK3360890T3 (da) Genterapi
DK3331529T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
EP3290364A4 (en) Conveyor belt wear monitoring system
DK3270930T3 (da) Præeklampsi
DK3394281T3 (da) Gærcelle
DK3099791T3 (da) Protein
EP3363322A4 (en) Hair extender
DK3292136T3 (da) Penicillin-g-acylaser
DE112015006486A5 (de) Inkubationsrinne
DK3448879T3 (da) Claudin-6 peptider
DK3274482T3 (da) Stenborsknop
HRP20182029T1 (hr) Uti-fuzijski proteini
DE102015206660A8 (de) Plattenaufteilanlage
DK3099793T3 (da) Protein
DK3318308T3 (da) Badmintonketsjer
DE112015005904A5 (de) Gurtschlossbringer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180323

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190328

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/435 20060101ALI20190322BHEP

Ipc: A61K 51/08 20060101ALI20190322BHEP

Ipc: C07K 14/00 20060101ALI20190322BHEP

Ipc: C07K 14/51 20060101ALI20190322BHEP

Ipc: A61K 38/16 20060101AFI20190322BHEP

Ipc: A61K 47/64 20170101ALI20190322BHEP

Ipc: A61K 47/62 20170101ALI20190322BHEP

Ipc: A61K 49/00 20060101ALI20190322BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210128

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BLAZE BIOSCIENCE, INC.

Owner name: FRED HUTCHINSON CANCER CENTER

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250401